Ophthalmic formulations including selective alpha 1 antagonists
US8889112B2 · kind B2 · utility
19Cited by
26References
44Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jun 14, 2004 |
| Grant date | Nov 18, 2014 |
| Priority date | — |
| Expiry date | Feb 5, 2028 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Ophthalmic formulations are provided. The ophthalmic formulations include one or more active agents that act to optimize pupil light reflex while minimizing, or effectively eliminating, any undesired eye redness in response to application thereof. The active agents include, for example, alpha 1 antagonists, such as alpha 1a selective antagonists.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.